Journal of Clinical Oncology, Vol 12, 1764-1770, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

M Spielmann, T Dorval, F Turpin, E Antoine, M Jouve, F Maylevin, D Lacombe, J Rouesse, P Pouillart and T Tursz
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

PURPOSE: The study investigated the therapeutic effects of a combination of Navelbine (vinorelbine or 5'noranhydrovinblastine; Pierre Fabre Medicament, Boulogne, France) and doxorubicin in women who had received no prior chemotherapy for locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Ninety-seven patients with progressive and assessable advanced or metastatic breast cancer who had received no prior chemotherapy except in an adjuvant setting were entered onto the study. Eighty-nine patients were assessable for toxicity and response by World Health Organization (WHO) criteria; the other eight patients were excluded because they did not meet entry criteria or because of protocol violations. Navelbine was administered at 25 mg/m2 by 30-minute intravenous (IV) infusion on days 1 and 8, and doxorubicin at 50 mg/m2 by slow IV infusion on day 1, with each course repeated at 3-week intervals. Patients were treated for a maximum of 11 cycles or until progression or major toxicity. RESULTS: Objective responses were observed in 66 of 89 assessable patients (74%; 95% confidence interval, 63% to 85%). There were nineteen (21%) complete responses (CRs) and 47 (53%) partial responses (PRs). In addition, 20 patients (22.5%) had stable disease and three (3.5%) progressed while on treatment. Responses were observed at all sites of metastatic disease. Forty-one of 58 patients with visceral disease responded (71%) and 25 of 31 with soft tissue and bone disease experienced an objective response (81%). The median duration of response was 12 months (range, 2.4 to 40.5), and the median overall survival was 27.5 months (range, 4 to 46). Neutropenia was dose-limiting, with 36 patients (41%) experiencing grade 3 or 4 toxicity. Of 727 cycles administered, there were 20 admissions (3%) for treatment of febrile neutropenia, involving 14 of 89 patients (16%). Treatment-related cardiotoxicity at grade 2 to 4 was experienced by 10% of patients and necessitated the interruption of treatment in 1.5% of cycles. Other side effects were uncommon or manageable by conventional means. CONCLUSION: The encouraging response rates and duration achieved with this combination of Navelbine/doxorubicin under the conditions of this study deserve further randomized comparative trials with standard regimens.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M. Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist, June 1, 2006; 11(6): 563 - 573. [Abstract] [Full Text] [PDF]

				M. I. Zia, L. L. Siu, G. R. Pond, and E. X. Chen Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens J. Clin. Oncol., October 1, 2005; 23(28): 6982 - 6991. [Abstract] [Full Text] [PDF]

				C. Abrial, I. Van Praagh, R. Delva, B. Leduc, J. Fleury, E. Gamelin, I. Sillet-Bach, F. Penault-Llorca, S. Amat, and P. Chollet Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer Oncologist, April 1, 2005; 10(4): 242 - 249. [Abstract] [Full Text] [PDF]

				S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Ann. Onc., March 1, 2004; 15(3): 433 - 439. [Abstract] [Full Text] [PDF]

				G. Mustacchi, M. Muggia, S. Milani, R. Ceccherini, M. L. Leita, and C. Dellach A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer Ann. Onc., November 1, 2002; 13(11): 1730 - 1736. [Abstract] [Full Text] [PDF]

				I. Van Praagh, H. Cure, B. Leduc, S. Charrier, G. Le Bouedec, J.-L. Achard, J.-P. Ferriere, V. Feillel, M. de Latour, J. Dauplat, et al. Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer Oncologist, October 1, 2002; 7(5): 418 - 423. [Abstract] [Full Text] [PDF]

				P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al. First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694. [Abstract] [Full Text] [PDF]

				M. Pawlicki, J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, and P. Tomzak A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma Oncologist, June 1, 2002; 7(3): 205 - 209. [Abstract] [Full Text] [PDF]

				J. Bash-Babula, D. Toppmeyer, M. Labassi, J. Reidy, M. Orlick, R. Senzon, E. Alli, T. Kearney, D. August, W. Shih, et al. A Phase I/Pilot Study of Sequential Doxorubicin/Vinorelbine: Effects on p53 and Microtubule-associated Protein 4 Clin. Cancer Res., May 1, 2002; 8(5): 1057 - 1064. [Abstract] [Full Text] [PDF]

				J. Abrahamova, M. Wagnerova, E. Kubala, V. Malec, E. Simova, I. Sirakova, E. Pavlikova, D. Machova, I. Kocak, I. Pavlikova, et al. Vinorelbine, Epirubicin, and Methotrexate (VEM) as Primary Treatment in Locally Advanced Breast Cancer Oncologist, August 1, 2001; 6(4): 347 - 352. [Abstract] [Full Text] [PDF]

				G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515. [Abstract] [Full Text] [PDF]

				H. S. Hochster, C. L. Vogel, S. L. Burman, and R. White Activity and Safety of Vinorelbine Combined with Doxorubicin or Fluorouracil as First-Line Therapy in Advanced Breast Cancer: A Stratified Phase II Study Oncologist, June 1, 2001; 6(3): 269 - 277. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]

				B. Norris, K. I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, et al. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol., June 12, 2000; 18(12): 2385 - 2394. [Abstract] [Full Text] [PDF]